Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Histerectomía por orificio natural transvaginal Cirugía endoscópica transluminal versus histerectomía laparoscópica (vNOTESHC)

29 de septiembre de 2026 actualizado por: Centre Hospitalier Universitaire de Saint Etienne

vNOTESHC: Histerectomía por cirugía endoscópica transluminal transvaginal con orificio natural versus histerectomía laparoscópica: un ensayo controlado aleatorizado

In France, there are approximately 62,000 hysterectomies per year, 70% of which are benign. It is the most frequent surgical procedure in gynecology.

Hysterectomies are performed via 3 routes: laparotomy, laparoscopy or vaginal route.

This choice of approach is particularly important in the case of large uteri (50% of uteri > 280g), which increase the risks of laparoconversion and bladder injury (NP3).

The vaginal route reduces the operating time and postoperative pain. Laparoscopy allows a better anatomical view and easier access to the neighbouring organs, which makes it the preferred approach, especially for young surgeons and when the uterus is large. However, the laparoscopic route is associated with an increase in the rate of conversion to laparotomy according to the volume of the uterus, as well as the rate of general per and postoperative complications compared with vaginal hysterectomy for uteri > 280 g. In a meta-analysis comparing laparoscopy and vaginal hysterectomy, the total prevalence of perioperative complications according to the classification of Clavien and Dindo was 27%. For large uteruses, complications by the vaginal route amounted to 15% and those by the laparoscopic route to 37.5%.

The data are not sufficient to give preference to one or other of the approaches, but for benign pathologies, for large uteri (>280 g), the minimally invasive laparoscopic or vaginal approaches are recommended by the CNGOF (grade C).

A new Medical Device (MD), the vNOTES (Vaginal Natural Orifice Transluminal Endoscopy System) offers the advantage of two approaches for pelvic surgery by allowing minimally invasive surgery to be performed by endoscopy through the vagina, offering perfect vision for the assistants and the operator and without scarring. Two randomized trials have shown that vNOTES allows, compared to laparoscopy, to perform adnexectomies and hysterectomies without conversion with less pain, fewer postoperative complications and a shorter hospitalization time.

The first evaluations of vNOTES are encouraging and suggest a new era for pelvic surgery: less postoperative pain, fewer complications and facilitation of ambulatory care. Also the videoscopic assistance of the vNOTES is a pedagogical tool for the vaginal route because the field of vision is no longer limited to the operator alone. However, the vNOTES has only been evaluated by the developers of the tool, in monocentric studies and in small numbers. The hysterectomy study evaluated only 35 patients with vNOTES, half of whom had a uterus of less than 280 g. The benefit of vNOTES for uteri smaller than 280 g is not obvious because of the ease of the surgical procedure and the cost of the "classic" vaginal route. Our study would be the first multicentric and academic study on vNOTES to focus specifically on large volume uteri, the most difficult to operate and prone to postoperative complications.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Bron, Francia, 69677
        • Aún no reclutando
        • HFME - Hospices Civils de Lyon
        • Investigador principal:
          • Géry LAMBLIN
        • Contacto:
      • Clermont-Ferrand, Francia, 63003
        • Reclutamiento
        • CHU Clermont-Ferrand
        • Sub-Investigador:
          • Sandra CURINIER, PH
        • Contacto:
        • Investigador principal:
          • Sandrine CAMPAGNE-LOISEAU, PH
      • Issoire, Francia, 63500
        • Aún no reclutando
        • Ch Issoire
        • Contacto:
        • Investigador principal:
          • Aslam MANSOOR, PH
      • Limoges, Francia, 87042
        • Aún no reclutando
        • CHU LIMOGES - Hôpital de la mère et de l'Enfant
        • Contacto:
      • Saint-Etienne, Francia, 42100
        • Aún no reclutando
        • Clinique Mutualiste de Saint-Etienne
        • Contacto:
        • Investigador principal:
          • Quentin REBOUL, MD
      • Saint-Etienne, Francia, 42055
        • Aún no reclutando
        • CHU Saint-Etienne
        • Contacto:
        • Investigador principal:
          • Thomas CORSINI
        • Sub-Investigador:
          • Céline CHAULEUR
        • Sub-Investigador:
          • Ahamd MEDHI

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Any woman received in preoperative consultation in the Gynecology-Obstetrics Department for a benign pathology of a uterus estimated to be large requiring a hysterectomy.
  • Patient affiliated or entitled to a social security system
  • Patients over 18 years of age
  • Patients having given their agreement to participate and after signing the consent form

Exclusion Criteria:

  • Woman refusing to participate in the study (lack of consent)
  • Non-French speaking woman (unable to conduct a good quality interview of the pregnant woman)
  • Participation in another interventional study.
  • Patient subject to a legal protection measure or unable to express her consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: laparoscopic hysterectomy

Laparoscopic Hysterectomy will be performed in a standardized manner with or without surgical robot

laparoscopic hysterectomy uses a standardized procedure with or without surgical robot

Experimental: natural vaginal orifice transluminal endoscopic system for hysterectomies (vNOTES)

Vaginal hysterectomy will be performed in a standardized manner using transluminal endoscopic system

hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of patient with complications
Periodo de tiempo: From surgery to 6 weeks of surgery

The proportion of patients with at least one pre- and post-operative complication at 6 weeks will be estimated along with its 95% confidence interval in each surgical strategy group.

The primary endpoint is a composite endpoint including the occurrence of intraoperative and postoperative complications within 6 weeks of surgery.

Postoperative complications were Infectious complications, Bleeding complications and All hospital readmissions related to the procedure Postoperative complications will be classified according to the Clavien-Dindo classification

Intraoperative complications will be defined as :

  • wounds of nearby organs (bladder, ureters, rectum, colon, small intestine)
  • and bleeding defined as bleeding requiring immediate resumption, intraoperative transfusion and/or decreasing the patient's hemoglobin by more than 2 points compared to the last known preoperative blood sample
From surgery to 6 weeks of surgery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Conversion
Periodo de tiempo: During surgery

Number of patients with conversion during surgery

During surgery

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Post-operative pain
Periodo de tiempo: From surgery to 3 hours of surgery

Maximal Pain measured by a numerical scale : 0 no pain / 10 maximum pain

From surgery to 3 hours of surgery
Short-term postoperative pain
Periodo de tiempo: From surgery to 1 week after surgery

Maximal short-term postoperative pain the first week after surgery measured by a numerical scale (0 no pain / 10 maximum pain) by a daily telephone call

From surgery to 1 week after surgery
Duration of postoperative reflex ileus
Periodo de tiempo: Day 0

Duration of post-operative reflex ileus between the day of the operation and the resumption of a transit (appearance of the first gas) in hours

Day 0
Duration of the operation
Periodo de tiempo: Surgery

operative time will be evaluated between the incision and the end of the closure, in minutes.

Surgery
Duration of hospitalization and the possibility of returning home
Periodo de tiempo: last day of hospitalization

The length of hospital stay will be assessed in days and the possibility of return home by the time in hours from surgical incision to a Chung≥ score of 9/10. The Chung score assesses the possibility of a return home in ambulatory surgery.

last day of hospitalization
Sexual dysfunction
Periodo de tiempo: 3 months

Sexual disorders: sexual life will be assessed by the difference in the specific validated score (self-questionnaire) (PISQ12 with a score ranging from 0 to 48) between the inclusion date and 3 months after surgery for sexually active women.

3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Céline CHAULEUR, PhD, Centre Hospitalier Universitaire de Saint Etienne

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

23 de diciembre de 2024

Finalización primaria (Estimado)

1 de octubre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

4 de mayo de 2023

Primero enviado que cumplió con los criterios de control de calidad

22 de mayo de 2023

Publicado por primera vez (Actual)

1 de junio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 21PH265
  • 2023-A01013-42 (Otro identificador: ANSM)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir